



Company Contact – Jim Dorsey
BioClinica, Inc.
267-757-3040

Investor Contact – Linda Decker
Financial Media – Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

Trade Media Contact – Brian Gawron
Diccicco Battista Communications
215-957-0300

FOR IMMEDIATE RELEASE

BIOCLINICA TO PRESENT AT SIDOTI & COMPANY'S FIRST 2010

MICRO CAP CONFERENCE ON JANUARY 11, 2010

NEWTOWN, PA, January 5, 2010 – BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services,, will be presenting at the Sidoti & Company's First 2010 Micro Cap Conference on January 11, 2010 at 9:50 a.m. EST at the Grand Hyatt Hotel in New York City.

Mark L. Weinstein, President and CEO of BioClinica will be reviewing the company's robust suite of clinical trial services and provide an update on its business.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States and Europe. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####